A platform-based diagnostics company building affordable tests for every stage of disease - and betting the biggest unmet need is in emerging markets, not just wealthy ones.
Founded 2019 in Singapore. Corporate & R&D in Singapore, manufacturing in Suzhou, clinical labs in Beijing. Six diagnostic platforms under one roof. Photographed here: the Virtue wordmark.
Virtue Diagnostics is an in vitro diagnostics (IVD) company - it makes the instruments and reagents that clinical laboratories use to detect and monitor disease. Rather than specializing in a single test type, Virtue is a platform company, developing a spread of technologies that together cover a patient's whole journey: early screening, initial diagnosis, treatment monitoring, and minimal residual disease management.
Its focus areas are infectious disease, cancer and chronic disease. The portfolio spans chemiluminescence immunoassays, clinical chemistry and hematology analyzers, clinical mass spectrometry, multiplex immunohistochemistry (mIHC) and digital pathology, and molecular diagnostics - with single-cell technology feeding biomarker discovery. In practical terms, Virtue builds the machines that measure what is happening inside the body, plus the consumable kits that keep those machines running.
The company was founded in 2019 and is led by CEO Johnson Zhang. It keeps corporate and R&D functions in Singapore, manufacturing in Suzhou, China, and a contract-research organization and clinical laboratory in Beijing - a deliberately distributed structure for a young company.
Virtue designs its platforms to follow a patient across the full arc of disease, rather than stopping at the single most profitable moment.
Catching disease signals before symptoms appear.
Confirming and characterizing the condition.
Tracking response and adjusting therapy.
Watching for minimal residual disease and relapse.
An automated clinical mass-spec platform including a triple quadrupole mass spectrometer that received China NMPA approval and launched in Q3 2021, developed under an exclusive China partnership with PerkinElmer.
Launched Q3 2021Automated chemiluminescence detection systems and reagent kits for immunoassay-based diagnostics across infectious disease, cancer and chronic-disease markers.
Cost-effective multiplex immunohistochemistry and multiplex tissue analysis via the Panovue landscape-analysis platform, acquired in 2021.
Panovue acquired 2021Molecular assays and systems for infectious diseases and cancer, covering genomic and proteomic biomarker detection.
Automated clinical chemistry and hematology analyzers with reagents for everyday laboratory testing.
A single-cell analysis platform supporting biomarker discovery and advanced molecular-biology applications.
"Virtue has high potential to be a global leader."
Primary geographies: China, Singapore, Brazil, Indonesia and the Philippines.
Advanced diagnostics - mass spectrometry, multiplex pathology, molecular testing - are often priced and distributed for wealthy, developed-market labs. That leaves large populations in emerging economies without access to the tests that decide how medicine begins.
Virtue's answer is localized innovation: manufacture affordably, adapt to local clinical workflows, and expand through the markets big vendors tend to overlook.
The IVD market is dominated by global incumbents - Roche Diagnostics, Abbott, Siemens Healthineers, Danaher and Thermo Fisher - and, in China, by established players such as Mindray, Snibe and Autobio. Virtue does not try to out-scale them in developed markets. Instead it positions on two axes: breadth of platform and affordability for emerging markets.
Where a competitor might sell one dominant assay line, Virtue assembles six platforms under one company so a laboratory can standardize across screening, diagnosis, monitoring and pathology. And where premium diagnostics can be out of reach, Virtue's manufacturing base in Suzhou and its localized-innovation model aim to bring the price down without abandoning technical ambition - visible in its NMPA-approved mass spectrometer and its cost-conscious multiplex pathology.
B2B medical-device and diagnostics manufacturing. Virtue sells instruments - analyzers, mass spectrometers, pathology workstations - alongside recurring-revenue consumables such as reagents and assay kits.
A team combining Chinese operating experience with international exposure - a mix investors singled out.
Established as a platform IVD company with corporate and R&D headquarters in Singapore.
Launches an NMPA-approved triple quadrupole clinical mass spectrometer and acquires multiplex pathology firm Panovue.
Closes a $100 million round led by Sequoia China and Morningside Ventures to fund emerging-market expansion.
Receives a 2023 Best IVD Enterprise industry award.
US$100,000,000
Co-led by Sequoia China and Morningside Ventures, with ORIZA Holdings, Lilly Asia Ventures and PerkinElmer Ventures participating. HAOYUE Capital advised. Total reported funding: ~US$130M.
"Virtue is unique in having successful entrepreneurial experience in China combined with international exposure."
Virtue deliberately separates R&D (Singapore), manufacturing (Suzhou) and clinical/CRO work (Beijing) - each site chosen for what it does best.
Its Singapore HQ at 35 Mandalay Road sits within the Novena / Tan Tock Seng hospital district - fitting for a diagnostics company.
Around 46 people coordinate instruments and reagents across multiple emerging-market geographies. Reach comes from platforms, not headcount.
The cap table pairs a top venture firm (Sequoia China) with a diagnostics corporate investor (PerkinElmer Ventures) that is also a commercial partner.
It is a platform-based in vitro diagnostics company that develops and manufactures diagnostic instruments and reagents - across chemiluminescence, clinical chemistry, hematology, clinical mass spectrometry, multiplex immunohistochemistry and molecular diagnostics - for infectious disease, cancer and chronic disease.
Its corporate and R&D headquarters are in Singapore (35 Mandalay Road), with manufacturing in Suzhou, China and a CRO/clinical laboratory in Beijing.
Virtue Diagnostics was founded in 2019 and is led by CEO Johnson Zhang.
It closed a US$100 million Series B in January 2022 led by Sequoia China and Morningside Ventures, with ORIZA Holdings, Lilly Asia Ventures and PerkinElmer Ventures participating. Total reported funding is around US$130 million.
It focuses on localized innovation for emerging markets, including China, Singapore, Brazil, Indonesia and the Philippines.
Video: no official Virtue Diagnostics interview or product-demo video was verifiable at publication. Search "Virtue Diagnostics" on YouTube for the latest uploads.